{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05254795",
            "orgStudyIdInfo": {
                "id": "MCC-21-LUN-126-PMC"
            },
            "organization": {
                "fullName": "University of Kentucky",
                "class": "OTHER"
            },
            "briefTitle": "Precision Medicine Randomized Clinical Trial Comparing Molecular Tumor Board Assisted Care to Usual Care",
            "officialTitle": "Precision Medicine Randomized Clinical Trial Comparing Molecular Tumor Board Assisted Care to Usual Care",
            "acronym": "PRiMAL",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "precision-medicine-randomized-clinical-trial-comparing-molecular-tumor-board-assisted-care-to-usual-care"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-04-13",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2036-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-02-14",
            "studyFirstSubmitQcDate": "2022-02-14",
            "studyFirstPostDateStruct": {
                "date": "2022-02-24",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-09",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-11",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR_INVESTIGATOR",
                "investigatorFullName": "Timothy Mullett",
                "investigatorTitle": "Professor",
                "investigatorAffiliation": "University of Kentucky"
            },
            "leadSponsor": {
                "name": "Timothy Mullett",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Eli Lilly and Company",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This trial will compare Molecular Tumor Board (MTB) assisted care to usual care for patients who have newly diagnosed histologically or cytologically confirmed stage IIb-IV Non-Small Cell Lung Cancer (NSCLC) and are planning to undergo treatment for their cancer."
        },
        "conditionsModule": {
            "conditions": [
                "Non-Small Cell Lung Cancer"
            ],
            "keywords": [
                "Molecular tumor board"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "OTHER",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 500,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Usual care recipients",
                    "type": "NO_INTERVENTION"
                },
                {
                    "label": "Molecular tumor board intervention",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Other: Molecular tumor board assisted care"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "OTHER",
                    "name": "Molecular tumor board assisted care",
                    "description": "Participants in this group will obtain recommendations for care from the molecular tumor board.",
                    "armGroupLabels": [
                        "Molecular tumor board intervention"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Overall survival",
                    "description": "Overall survival 1 year survival between individuals with stage IIb-IV NSCLC who receive MTB assisted care to those who receive usual care.",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "Change in quality of life (QOL)",
                    "description": "Quality of life will be assessed via the FACT-L (The Functional Assessment of Cancer Therapy - Lung). FACT-L has 5 areas of measurement: physical wellbeing, social/family wellbeing, emotional wellbeing, functional wellbeing, and an additional concerns list of problems specific to lung cancer. Areas are measured on a 5-point Likert-type scale of 0-4. The FACT-L subscales can be scored to yield a total score, subscale scores, as well as the Trial Outcome Index (TOI), which reflects the physical wellbeing, functional wellbeing, and lung cancer symptom subscales. TOI scores range from 0-84, with a higher score reflecting better QOL. Total FACT-G scores (physical, social, emotional, and functional wellbeing subscales) range from 0-108, with higher scores reflecting better QOL. The lung cancer subscale (i.e., additional concerns subscale) can range from 0-28 (only 7 items are scored), with higher scores reflecting better QOL.",
                    "timeFrame": "At enrollment, 8 weeks, and 12 weeks."
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Overall survival",
                    "description": "Comparison of overall survival between individuals with stage IIb-IV NSCLC who receive MTB assisted care to those who receive usual care",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "Change in guideline concordant care",
                    "description": "Comparison of guideline concordant care (specifically receiving next generation sequencing (NGS) testing and treatments based on identified mutations) between individuals with stage IIb-IV NSCLC who receive MTB assisted care to those who receive usual care.",
                    "timeFrame": "8 weeks, 12 weeks, and 1 year"
                },
                {
                    "measure": "Change in satisfaction with treatment",
                    "description": "To compare satisfaction with treatment between individuals with stage IIb-IV NSCLC who receive MTB assisted care to those who receive usual care, including financial, psychosocial, and physical measures of satisfaction using the Functional Assessment of Chronic Illness Therapy (FACIT) - Treatment Satisfaction - General (TSG) (version 4). The FACIT-TSG is an 8-item questionnaire, with each item score ranging from 0 (\"not at all\") to 4 (\"very much\"). Total scores range from 0 to 32 with higher scores indicating greater satisfaction with treatment.",
                    "timeFrame": "At enrollment, 8 weeks, and 12 weeks."
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Association of ctDNA variant allele frequency",
                    "description": "To determine the association of ctDNA variant allele frequency with 1 year overall survival",
                    "timeFrame": "1 year"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Clinically suspected or histologically confirmed stage IIb-IV NSCLC who are planning to undergo treatment\n* No prior systemic therapies for NSCLC, with the exception of adjuvant therapy for early stage NSCLC. Prior surgery and/or radiation is allowed.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with targeted therapy, in the opinion of the treating physician.\n* Pregnancy",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "120 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Timothy Mullett, MD",
                    "role": "CONTACT",
                    "phone": "8592186647",
                    "email": "timothy.mullett@uky.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Timothy Mullett, MD",
                    "affiliation": "University of Kentucky",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Kentucky",
                    "status": "RECRUITING",
                    "city": "Lexington",
                    "state": "Kentucky",
                    "zip": "40506",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Timothy Mullett, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.98869,
                        "lon": -84.47772
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002289",
                    "term": "Carcinoma, Non-Small-Cell Lung"
                }
            ],
            "ancestors": [
                {
                    "id": "D000002283",
                    "term": "Carcinoma, Bronchogenic"
                },
                {
                    "id": "D000001984",
                    "term": "Bronchial Neoplasms"
                },
                {
                    "id": "D000008175",
                    "term": "Lung Neoplasms"
                },
                {
                    "id": "D000012142",
                    "term": "Respiratory Tract Neoplasms"
                },
                {
                    "id": "D000013899",
                    "term": "Thoracic Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008171",
                    "term": "Lung Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5546",
                    "name": "Carcinoma, Non-Small-Cell Lung",
                    "asFound": "Non-small Cell Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M5540",
                    "name": "Carcinoma, Bronchogenic",
                    "relevance": "LOW"
                },
                {
                    "id": "M5260",
                    "name": "Bronchial Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M14979",
                    "name": "Respiratory Tract Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M16658",
                    "name": "Thoracic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11168",
                    "name": "Lung Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}